# Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）

> **NCT05119972** · PHASE1,PHASE2 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 15 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** ZSP1603
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05119972
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119972, "Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05119972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*